Literature DB >> 33941214

Risk factors for central lymph node metastasis in the cervical region in papillary thyroid carcinoma: a retrospective study.

Xiang Li1, Hanwen Zhang1, Yu Zhou1, Ruochuan Cheng2.   

Abstract

BACKGROUND: To investigate the influence of different risk factors on central lymph node metastasis (CLNM) in the cervical region in patients with papillary thyroid carcinoma (PTC).
METHODS: This retrospective study included 2586 PTC patients. Potential risk factors were identified by univariate analysis, and the relationships between these factors and CLNM were ascertained by multivariable analysis. A scoring system was constructed, and the optimal cut-off value was determined.
RESULTS: On univariate analysis, sex, age, tumor diameter, multifocality, capsule invasion, vascular invasion, total number of lymph nodes in the central region, and serum thyroid peroxidase antibody (TPOAb) concentration were identified as potential risk factors for CLNM in the cervical region, whereas nerve invasion, thyroid-stimulating hormone concentration, and thyroglobulin antibody (TgAb) concentration were not. Multivariable analysis indicated that male sex, young age, large tumor diameter, multifocality, vascular invasion, a large number of central lymph nodes, and a low TPOAb concentration were significant risk factors. From these factors, a preoperative CLNM risk assessment scale was constructed for predicting CLNM in the cervical region for PTC patients.
CONCLUSION: Male sex, young age, large tumor diameter, multifocality, vascular invasion, a large number of central lymph nodes, and a low TPOAb concentration were positively correlated with CLNM in the cervical region in PTC patients. The preoperative CLNM risk assessment scale based on these risk factors is expected to offer accurate preoperative assessment of central lymph node status in PTC patients.

Entities:  

Keywords:  Central lymph node metastasis (CLNM); papillary thyroid carcinoma (PTC); retrospective study; risk factor

Year:  2021        PMID: 33941214     DOI: 10.1186/s12957-021-02247-w

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   2.754


  6 in total

1.  Evaluate the diagnostic and prognostic value of NUSAP1 in papillary thyroid carcinoma and identify the relationship with genes, proteins, and immune factors.

Authors:  Tiantian Gao; Lei Zhao; Fan Zhang; Conghui Cao; Shuting Fan; Xiaoguang Shi
Journal:  World J Surg Oncol       Date:  2022-06-16       Impact factor: 3.253

2.  Minimal extrathyroidal extension is associated with lymph node metastasis in single papillary thyroid microcarcinoma: a retrospective analysis of 814 patients.

Authors:  Ra-Yeong Song; Hee Sung Kim; Kyung Ho Kang
Journal:  World J Surg Oncol       Date:  2022-05-28       Impact factor: 3.253

Review 3.  Recent advances in cancer immunotherapy.

Authors:  Qiang Sun; Gerry Melino; Ivano Amelio; Jingting Jiang; Ying Wang; Yufang Shi
Journal:  Discov Oncol       Date:  2021-08-18

4.  Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma - Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015.

Authors:  Agnieszka Czarniecka; Marcin Zeman; Grzegorz Wozniak; Adam Maciejewski; Ewa Stobiecka; Ewa Chmielik; Malgorzata Oczko-Wojciechowska; Jolanta Krajewska; Daria Handkiewicz-Junak; Barbara Jarzab
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-06       Impact factor: 5.555

5.  Application of Preoperative Ultrasonography in the Diagnosis of Cervical Lymph Node Metastasis in Thyroid Papillary Carcinoma.

Authors:  Ailong Zhang; Shenglan Wu; Zhenhui You; Wenkai Liu
Journal:  Front Surg       Date:  2022-02-28

6.  Risk Factors for Central Lymph Node Metastases and Benefit of Prophylactic Central Lymph Node Dissection in Middle Eastern Patients With cN0 Papillary Thyroid Carcinoma.

Authors:  Sandeep Kumar Parvathareddy; Abdul K Siraj; Saeeda O Ahmed; Felisa DeVera; Saif S Al-Sobhi; Fouad Al-Dayel; Khawla S Al-Kuraya
Journal:  Front Oncol       Date:  2022-01-17       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.